Literature DB >> 2468619

Inhibition of histamine and prostaglandin D2 release from human lung mast cells by ciclosporin A.

M Triggiani1, R Cirillo, L M Lichtenstein, G Marone.   

Abstract

Cyclosporin A (CsA) is now widely used in the prevention/treatment of graft rejection and in the treatment of some human inflammatory diseases. We studied the effect of CsA on the release of chemical mediators from human lung mast cells in vitro. CsA (0.03-3 micrograms/ml) inhibited the release of histamine and prostaglandin D2 induced by anti-IgE from lung mast cells. CsA-induced inhibition of mediator release was not abolished by washing the cells before stimulation and it was not affected by the degree of purity of mast cell preparations. Our results indicate that CsA, in pharmacological concentrations, is a rapid and irreversible inhibitor of the release of preformed and de novo synthesized mediators from human lung mast cells. These findings might explain, at least in part, some of the therapeutic actions of CsA in vivo.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2468619     DOI: 10.1159/000234801

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  9 in total

Review 1.  Future modalities.

Authors:  M W Greaves
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

2.  Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506.

Authors:  C A Harrison; R Bastan; M J Peirce; M R Munday; P T Peachell
Journal:  Br J Pharmacol       Date:  2007-01-02       Impact factor: 8.739

3.  Effect of cyclosporin-A on histamine release from tracheal strips of sensitized guinea pigs.

Authors:  M Bovingdon; E S Assem; B Y Wan
Journal:  Inflamm Res       Date:  1996-03       Impact factor: 4.575

4.  Lack of inhibition by cyclosporin in the Schultz-Dale reaction.

Authors:  E S Assem; C I Ezeamuzie; B Y Wan; Y Ayalew
Journal:  Inflamm Res       Date:  1995-04       Impact factor: 4.575

5.  Inhibition of histamine release from human lung and rat peritoneal mast cells by cyclosporin-A.

Authors:  I C Ezeamuzie; E S Assem
Journal:  Agents Actions       Date:  1990-04

Review 6.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

7.  Cyclosporine is angiostatic.

Authors:  K Norrby
Journal:  Experientia       Date:  1992-12-01

8.  NFAT but not NF-kappaB is critical for transcriptional induction of the prosurvival gene A1 after IgE receptor activation in mast cells.

Authors:  Erik Ullerås; Mats Karlberg; Christine Möller Westerberg; Jessica Alfredsson; Steve Gerondakis; Andreas Strasser; Gunnar Nilsson
Journal:  Blood       Date:  2008-01-08       Impact factor: 22.113

9.  Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A?

Authors:  N H Sigal; F Dumont; P Durette; J J Siekierka; L Peterson; D H Rich; B E Dunlap; M J Staruch; M R Melino; S L Koprak
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.